ContraFect (NASDAQ:CFRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of ContraFect (NASDAQ:CFRX – Get Rating) in a report released on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, SVB Leerink decreased their target price on shares of ContraFect from $14.00 to $9.00 and set an outperform rating for the company in a research note on Wednesday, February 16th.

Shares of NASDAQ CFRX opened at $3.83 on Monday. ContraFect has a 12 month low of $2.11 and a 12 month high of $4.76. The company has a 50 day simple moving average of $3.41 and a two-hundred day simple moving average of $3.29. The stock has a market cap of $150.65 million, a price-to-earnings ratio of -6.84 and a beta of 0.57.

ContraFect (NASDAQ:CFRX – Get Rating) last posted its earnings results on Thursday, March 24th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.13. Sell-side analysts forecast that ContraFect will post -1.19 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Telemetry Investments L.L.C. boosted its position in shares of ContraFect by 2.4% during the 3rd quarter. Telemetry Investments L.L.C. now owns 134,382 shares of the biotechnology company’s stock valued at $544,000 after acquiring an additional 3,134 shares during the last quarter. Morgan Stanley lifted its position in shares of ContraFect by 10.5% during the second quarter. Morgan Stanley now owns 43,060 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 4,083 shares in the last quarter. BlackRock Inc. lifted its position in shares of ContraFect by 0.8% during the fourth quarter. BlackRock Inc. now owns 530,194 shares of the biotechnology company’s stock worth $1,395,000 after purchasing an additional 4,293 shares in the last quarter. WealthTrust Axiom LLC lifted its position in shares of ContraFect by 20.0% during the fourth quarter. WealthTrust Axiom LLC now owns 30,025 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Wedmont Private Capital acquired a new stake in shares of ContraFect during the fourth quarter worth about $25,000. 58.44% of the stock is owned by institutional investors and hedge funds.

About ContraFect (Get Rating)

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides.

See Also